HIMS Stock Recent News

Hims & Hers stock is trading based on speculation about its success with weight loss drugs. But that's a very small part of its business.

Novo Nordisk and Eli Lilly are currently the major players in the weight loss market. Hims & Hers Health is looking to disrupt the space by offering a lower-cost alternative.

Hims & Hers' revenue and profit metrics soared in the second quarter. Growth is expected to accelerate in the second half following the launch of the company's GLP-1 offering.

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Hims just reported record Revenue, Profits, and Cash Flows, signifying improving fundamentals. This was driven by robust growth in its core offerings as well as the launch of its new Weight Loss offering. Demand for Hims products is so strong that management raised Revenue guidance by more than $100M.

Don't overlook the 52% growth in the second quarter.

Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder & CEO Yemi Okupe - CFO Conference Call Participants Maria Ripps - Canaccord Allen Lutz - Bank of America Jack Wallace - Guggenheim Securities Daniel Grosslight - Citi Jonna Kim - TD Cowen Aaron Kessler - Seaport Global Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Glen Santangelo - Jefferies George Hill - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers Second Quarter 2024 Earnings Conference Call.

Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago.

Shoppers might be spending less or seeking cheaper deals on takeout food and household items, and investors on Monday were panicking about the U.S. economy. But Hims & Hers Health Inc. — the online telehealth platform best known for selling hair-loss treatments, Viagra and Cialis — said customers are still piling in.

Palantir (PLTR) jumps on an earnings beat and increased A.I. demand. Kevin Green and Scott Durfey dive into A.I.